Wespeaker baselines for VoxSRC2023

This report showcases the results achieved using the wespeaker toolkit for the VoxSRC2023 Challenge. Our aim is to provide participants, especially those with limited experience, with clear and straightforward guidelines to develop their initial systems. Via well-structured recipes and strong results, we hope to offer an accessible and good enough start point for all interested individuals. In this report, we describe the results achieved on the VoxSRC2023 dev set using the pretrained models, you can check the CodaLab evaluation server for the results on the evaluation set

Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population.

Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (Pinteraction = 0.0058). These findings provide new insights into the etiology of lung adenocarcinoma in individuals from East Asian populations, which could be important in developing translational applications

Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (P interaction  = 0.0058). These findings provide new insights into the etiology of lung adenocarcinoma in individuals from East Asian populations, which could be important in developing translational applications

Using Feature-Oriented Analysis to Recover Legacy Software Design for Software Evolution

Most design recovery approaches start from analysing source code. Nonetheless, it is very difficult to get adequate design information only depending on source code. Additional available information is required and Feature Oriented Analysis (FOA) is a way to reach this aim. FOA addresses the understanding of features in software systems and defines mechanisms for carrying a feature from the problem domain into the solution domain. Using feature as the first-class entity for software evolution can improve program comprehension and design recovery. In this paper, an approach is proposed to recover software design based on the feature model, which is a kind of legacy system knowledge. The features will first be located and mapped to the implementation module so that feature-oriented components can be identified and retrieved, and then, through the analysis of the feature relations, the design model of legacy system can be recovered and used for the future evolution

Unlocking Novel Ultralow-Frequency Band Gap: Assembled Cellular Metabarrier for Broadband Wave Isolation

Admittedly, the design requirements of compactness, low frequency, and broadband seem to constitute an impossible trinity, hindering the further development of elastic metamaterials (EMMs) in wave shielding engineering. To break through these constraints, we propose theoretical combinations of effective parameters for wave isolation based on the propagation properties of Lamb waves in the EMM layer. Accordingly, we design compact EMMs with a novel ultralow-frequency bandgap, and the role of auxeticity in the dissociation between the dipole mode and the toroidal dipole mode is clearly revealed. Finally, under the guidance of the improved gradient design, we integrate multiple bandgaps to assemble metamaterial barriers (MMBs) for broadband wave isolation. In particular, the original configuration is further optimized and its ultralow-frequency and broadband performance are proven by transmission tests. It is foreseeable that our work will provide a meaningful reference for the application of the new EMMs in disaster prevention and protection engineering

Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal (GI) peptide hormone that stimulates insulin secretion, gene expression and β-cell proliferation, representing a potentially novel and promising therapeutic agent for the treatment of T2DM. DPP-IV-resistant, long-acting GLP-1 analogs have already been approved by FDA as injectable drugs for treating patients with T2DM. Oral delivery of therapeutic peptides and proteins would be preferred owing to advantages of lower cost, ease of administration and greater patient adherence. However, oral delivery of proteins can be affected by rapid enzymatic degradation in the GI tract and poor penetration across the intestinal membrane, which may require amounts that exceed practical consideration. Various production strategies have been explored to overcome challenges associated with the oral delivery of therapeutic peptides and proteins. The goal of this review is to provide an overview of the current state of progress made towards the oral delivery of GLP-1 and its analogs in the treatment of T2DM, with special emphasis on the development of plant and food-grade bacterial delivery systems. Recently, genetically engineered plants and food-grade bacteria have been increasingly explored as novel carrier systems for the oral delivery of peptide and protein drugs. These have a largely unexplored potential to serve both as an expression system and as a delivery vehicle for clinically relevant, cost effective therapeutics. As such, they hold great promise for human biopharmaceuticals and novel therapies against various diseases

A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy

Liver hepatocellular carcinoma (LIHC) is the most common type of primary liver cancer. In the current study, genome-wide miRNA-Seq and mRNA profiles in 318 LIHC patients derived from The Cancer Genome Atlas (TCGA) were analysed to identify miRNA-based signatures for LIHC prognosis with survival analysis and a semi-supervised principal components (SPC) method. A seven-miRNA signature was confirmed for overall survival (OS) prediction by comparing miRNA profiles in paired primary tumour and solid tumour normal tissues. Thereafter, a linear prognostic model that consisted of seven miRNAs was established and used to divide patients into high- and low-risk groups according to prognostic scores. Subsequent Kaplan-Meier analysis revealed that the seven-miRNA signature correlated with a good predictive clinical outcome for 5-year survival in LIHC patients. Additionally, this miRNA-based prognostic model could also be used for OS prognosis of LIHC patients in early stages, which could guide the future therapy of those patients and promote the OS rate. Moreover, the seven-miRNA signature was an independent prognostic factor. In conclusion, this signature may serve as a prognostic biomarker and guide LIHC therapy, and it could even be used as an LIHC therapeutic target in the future

Table1_Diagnostic performance of GcfDNA in kidney allograft rejection: a meta-analysis.DOCX

In this comprehensive meta-analysis, our objective was to evaluate the diagnostic utility of graft-derived cell-free DNA (GcfDNA) in kidney allograft rejection and explore associated factors. We conducted a thorough search of PubMed, Embase, and the Cochrane Library databases, spanning from their inception to September 2022. Statistical analysis was executed utilizing Stata 15, Meta-DiSc 1.4, and Review Manager 5.4 software. The combined pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristics (SROC) curve from the synthesis of findings across ten studies were as follows: 0.75 (0.67–0.81), 0.78 (0.72–0.83), 3.36 (2.89–4.35), 0.32 (0.24–0.44), 8.77 (4.34–17.74), and 0.83 (0.80–0.86), respectively. Among the ten studies primarily focused on GcfDNA’s diagnostic potential for antibody-mediated rejection (ABMR), the optimal cut-off threshold demonstrated substantial diagnostic efficacy, with pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, DOR, and area under the summary receiver operating characteristics curve values of 0.83 (0.74–0.89), 0.75 (0.70–0.80), 3.37 (2.64–4.30), 0.23 (0.15–0.36), 14.65 (7.94–27.03), and 0.85 (0.82–0.88), respectively. These results underscore the high diagnostic accuracy of GcfDNA in detecting rejection. Furthermore, the optimal cut-off threshold proves effective in diagnosing ABMR, while a 1% threshold remains a robust diagnostic criterion for rejection. Notably, for ABMR diagnosis, droplet digital PCR digital droplet polymerase chain reaction emerges as a superior method in terms of accuracy when compared to other techniques. Nonetheless, further research is warranted to substantiate these findings.</p